Results 51 to 60 of about 2,816 (159)

Performance of QuantiFERON-TB Gold Plus assays in children and adolescents at risk of tuberculosis: a cross-sectional multicentre study.

, 2021
20.500.12530/87858The QuantiFERON-TB Gold Plus (QFT-Plus) assay, which features two antigen-stimulated tubes (TB1 and TB2) instead of a single tube used in previous-generation interferon-gamma release assays (IGRAs), was launched in 2016.
Soler-Garcia, Aleix, Korta Murua, José Javier, QFT-Plus Study Group of the Spanish Pediatric TB Research Network, Gamell, Anna, Tórtola, Teresa, Noguera-Julian, Antoni, Soriano-Arandes, Antonio, Rodríguez-Molino, Paula, Santiago, Begoña, Ruiz-Serrano, María Jesús, Piqueras, Ana Isabel, Pérez-Porcuna, Tomàs, Garrote-Llanos, María Isabel, Tagarro, Alfredo, Bustillo-Alonso, Matilde, Tebruegge, Marc, Monsonís, Manuel   +16 more
core   +2 more sources

Impact of an analytical intervention to assure the accuracy of LIAISON QuantiFERON-TB Gold Plus results. [PDF]

J Clin Microbiol
Pusz-Bochenska K, Banaei N.
europepmc   +3 more sources

First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting.

PLoS ONE, 2023
Diagnosis and treatment of tuberculosis infection (TBI) are the core elements of tuberculosis elimination. Interferon gamma release assays have advantages over the tuberculin skin test, although their implementation in low-resource settings is ...
Zirwatul Adilah Aziz, Noorliza Mohamad Noordin, Wan Mazlina Wan Mohd, Mohd Amin Kasim   +3 more
doaj   +1 more source

Prevalence of latent tuberculosis infection among foreign students tested with QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus

, 2016
Data used in the article ‘Prevalence of latent tuberculosis infection among foreign students tested with QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus' 
Elia Noemi Gallegos Morales (3378002)
core   +1 more source

Implementing contact tracing for tuberculosis in Kyrgyz Republic and risk factors for positivity using QuantiFERON-TB Gold plus

BMC Infectious Diseases, 2020
Background Effective active case finding (ACF) activities are essential for early identification of new cases of active tuberculosis (TB) and latent TB infection (LTBI).
Caroline Corbett, Aizat Kulzhabaeva, Tatjana Toichkina, Gulmira Kalmambetova, Sevim Ahmedov, Uladzimir Antonenka, Altyn Iskakova, Dilorom Kosimova, Dasha Migunov, Bakyt Myrzaliev, Evgeni Sahalchyk, Nagira Umetalieva, Monica Vogel, Abdylat Kadyrov, Harald Hoffmann   +14 more
doaj   +1 more source

The Value of the Second QuantiFERON-TB Gold-Plus Antigen Tube at Diagnosis and at Treatment Completion in Spanish Children With Tuberculosis

, 2023
20.500.12530/87857We studied 295 children (tuberculosis disease, n = 159; latent tuberculosis infection, n = 136) with positive QuantiFERON-TB Gold-Plus assay results.
Tomàs Pérez-Porcuna, Soler-Garcia, Aleix, QFT-Plus Study Group of the Spanish Pediatric TB Research Network, Aleix Soler-Garcia, Gamell, Anna, Noguera-Julian, Antoni, María Espiau, Elena Rincón-López, Rodríguez-Molino, Paula, Marc Tebruegge, Pérez-Porcuna, Tomàs, Bustillo-Alonso, Matilde, Begoña Santiago, Rincón-López, Elena, Korta-Murua, José Javier, Manuel Monsonís, Anna Gamell, Antoni Noguera-Julian, José Javier Korta-Murua, Santiago, Begoña, Paula Rodríguez-Molino, Espiau, María, Tebruegge, Marc, Matilde Bustillo-Alonso, Monsonís, Manuel   +24 more
core   +1 more source

A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent‐Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin‐producing pancreatic β‐cells. Preserving remaining β‐cells at the time of diagnosis may improve long‐term outcomes. Frexalimab is a humanised monoclonal antibody specific for CD40L undergoing evaluation for treatment of ...
Andriy Cherkas, Baerbel Rotthaeuser, Niels Porksen, Pascale Labard, My‐Liên Nguyên‐Pascal, Mathieu Coudert, Baptiste Berthou, Marie Baccara‐Dinet, Gabor Boka, Mark Peakman, Felix Reschke, Michael J. Haller   +11 more
wiley   +1 more source

Comparison of PPD and IGST Sensitivity in Latent Tuberculosis Assessment (Cross-sectional Study)

Sakarya Tıp Dergisi
Objective: Purified Protein Derivative (PPD) and Interferon Gamma Release Assay (IGRA) were performed on patients with ankylosing spondylitis and rheumatoid arthritis who were planned to initiate immunosuppressive treatment.
Nurhan Sarıoğlu, Nilay Şahin, Mustafa Çolak, Kazım Batıhan Büyükzengin, Fuat Erel, Hikmet Çoban   +5 more
doaj   +1 more source

Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD)

Diabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Introduction In 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of teplizumab (a monoclonal anti‐CD3 antibody) to delay progression from Stage 2 to Stage 3 Type 1 diabetes in the UK. Methods To address the need for clear guidance on managing patients eligible for teplizumab therapy, the British Society of ...
Renuka P. Dias, M. Loredana Marcovecchio, Ruben H. Willemsen, Fiona Campbell, Ahmad Ashour, Philip Newland‐Jones, Jennifer Cooper, Parth Narendran, Neil P. Wright   +8 more
wiley   +1 more source

Hepatic Sarcoidosis Unmasked by Chronic Pruritus and Esophageal Varices: A Case Report

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Sarcoidosis is a granulomatous disease that affects multiple organs, commonly the liver, with manifestations from asymptomatic disease to cirrhosis and liver failure. A 43‐year‐old male presented with generalized pruritus. Liver biopsy demonstrated findings consistent with sarcoidosis, and treatment was initiated. We emphasize timely follow‐up
Ming Zheng, Keroles Saadalla, Sandipa Sharma   +2 more
wiley   +1 more source